STOCK TITAN

XCELERATE INC - XCRT STOCK NEWS

Welcome to our dedicated page for XCELERATE news (Ticker: XCRT), a resource for investors and traders seeking the latest updates and insights on XCELERATE stock.

XCELERATE INC (XCRT) is a healthcare services and products company that focuses on integrating innovative technologies into the medical field. Established with a mission to revolutionize clinical care through the application of advanced engineering and intellectual property, Xcelerate operates in three main business areas:

  • Medical Technology and Virtual Health Services: Xcelerate is dedicated to extending the reach of physicians through AI and virtual health technology, especially targeting patients in developing countries.
  • Consumer Health and Beauty Products: The company formulates, packages, and markets clinically tested health and beauty products, including the Ceramedx® line, which features plant-based ceramide therapy for dry and sensitive skin.
  • Owning and Licensing Medical Equipment: Xcelerate holds and licenses various forms of medical equipment and a portfolio of patents and technology licenses.

Notable achievements include the recent publication of two utility patent applications by the United States Patent and Trademark Office, and the company's selection as an approved vendor for the Army & Air Force Exchange Service. Xcelerate is also actively involved in enhancing investor relations with the help of Darrow Associates and has partnered with Craft Capital Management to facilitate capital raising and advisory services.

With its headquarters in Mauldin, SC, Xcelerate is poised for significant growth and continues to develop its diverse range of healthcare solutions to improve global medical care.

Rhea-AI Summary

Xcelerate, Inc. (OTC PINK:XCRT) announced the acquisition of a patent portfolio from HS Pharmaceuticals LLC, enhancing its focus on dermatological products for chronic wounds and infections. The deal includes four issued and one pending U.S. patents, as well as two issued and one pending European patent, totaling millions in developmental costs. The acquisition involves issuing 10 million shares of restricted common stock and establishing a profit-sharing arrangement. This move aims to strengthen Xcelerate's technology base and aligns with its strategy to acquire cutting-edge medical innovations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
58.09%
Tags
-
Rhea-AI Summary

Xcelerate, Inc. (OTC Markets: XCRT) announced the engagement of SmallCapVoice.com, an investor relations firm, to enhance communication with shareholders. CEO Michael O'Shea highlighted the importance of this partnership in increasing corporate exposure and sharing developments at Xcelerate. The recent pilot program launch in Africa via its subsidiary, AfiyaSasa Africa, was noted as a significant milestone. SmallCapVoice.com aims to support Xcelerate's mission as a socially responsible global entity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.07%
Tags
none
-
Rhea-AI Summary

Xcelerate, Inc. (OTC Pink: XCRT) has initiated a pilot program in partnership with AfiyaSasa Africa, LLC to enhance healthcare delivery in Tanzania using AI and augmented reality. The company's 51% stake in ASA aims to address the shortage of medical professionals identified by Dr. Dilan Ellegala, who highlighted there were merely two neurosurgeons for 44 million people in the region. This innovative approach seeks to leverage advanced technology to improve medical services. More details can be found in the interview conducted by SmallCapVoice.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.49%
Tags
management
Rhea-AI Summary

Xcelerate, Inc. (OTC Markets:XCRT) has signed a Membership Interest Purchase Agreement to acquire a 51% interest in AfiyaSasa Africa, LLC, a medical technology and virtual health start-up founded by Dr. Dilan Ellegala and Doyle Word. Additionally, Xcelerate has obtained patent pending status for its invention, 'Surgical Tools with Targeting Guidance', aimed at enhancing surgical procedures through improved tool handling and precision. This represents the beginning of a series of planned patents as Xcelerate advances its mission of integrating engineering with clinical care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.86%
Tags
none
-
Rhea-AI Summary

Xcelerate, Inc. (OTCMarkets: XCRT) announced the appointment of Thomas E. Mannle, Jr. to its Advisory Board, effective immediately. Thomas, a retired Lieutenant Colonel from the U.S. Army Reserve, brings over 25 years of consulting experience in healthcare and defense. His expertise includes planning, budgeting, and technology integration in organizations. Xcelerate's CEO, Michael O'Shea, stated that Thomas would provide invaluable guidance on advancing their project alliance with AfiyaSasa Africa and the development of patentable med-tech. The company expressed gratitude to its partners and investors for their support.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.51%
Tags
management
-
Rhea-AI Summary

Xcelerate, Inc. (OTC PINK:XCRT) has acquired majority control of AfiyaSasa Africa, LLC, which focuses on medical technology for developing countries. A pilot program will launch in Tanzania across four hospitals, potentially expanding to a fifth location. The program aims to establish operational beta sites by Q2 2022 and generate revenue by the end of 2022. CEO Michael O'Shea highlighted the team's rapid progress and plans to up-list to the QB market to attract more investors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
Rhea-AI Summary

On March 10, 2022, Xcelerate (OTC Pink: XCRT) CEO Michael O’Shea discussed the company's innovative use of artificial intelligence (AI) to enhance healthcare access in remote areas of Tanzania. The AI-driven software, initially designed for self-driving cars, allows patients to connect with healthcare professionals via mobile devices, improving treatment efficiency. Xcelerate aims to launch a beta site by Q2 2022 and anticipates generating revenue by year-end. Additionally, the company plans to file several patents related to its technology, aiming for an uplisting to OTCQB.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
none
-
Rhea-AI Summary

Xcelerate, Inc. (OTC Pink: XCRT) has acquired a 51% stake in AfiyaSasa Africa, LLC to improve healthcare access in Africa. CEO Michael O’Shea announced that Dr. Dilan Elegalla has moved to Tanzania to lead a pilot program, with Sriyanjit Perera as CEO of ASA. The initiative aims to utilize patented telemedicine technology to connect patients with physicians via mobile devices. With 650 million mobile users in Africa, ASA expects to launch a fully operational beta site by the end of Q2 2022 and become revenue-producing before year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.76%
Tags
none
-
Rhea-AI Summary

Xcelerate (OTC Pink: XCRT) has announced the appointment of Fran White to its Advisory Board, effective immediately. With over 40 years of experience, White founded MDC Associates, a consulting firm in regulatory affairs for the medical device and biotechnology sectors. Her expertise is expected to enhance Xcelerate's upcoming patent filings and support their business expansion in Africa through AfiyaSasa Africa, LLC. CEO Michael O’Shea highlighted her invaluable skills in recognizing market opportunities, particularly in developing regions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
management
Rhea-AI Summary

Xcelerate (OTC Pink: XCRT) announced on January 25, 2022, that it filed a Supplemental Report with OTC Markets to remove its 'shell' status. CEO Michael O’Shea stated that following their recent Form 1-A filing with the SEC, the company believes it no longer qualifies as a shell under SEC rules. This change is a step toward Xcelerate's goal of uplisting to the OTCQB and ultimately to a national exchange.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
none

FAQ

What is the current stock price of XCELERATE (XCRT)?

The current stock price of XCELERATE (XCRT) is $0.02215 as of October 15, 2024.

What is the market cap of XCELERATE (XCRT)?

The market cap of XCELERATE (XCRT) is approximately 10.7M.

What does Xcelerate Inc. do?

Xcelerate Inc. integrates advanced engineering technologies into medical applications, markets health and beauty products, and licenses medical equipment.

How does Xcelerate contribute to healthcare?

Xcelerate extends physician reach through virtual health technology and provides clinically tested health and beauty products.

What recent patents has Xcelerate published?

Xcelerate has published utility patent applications US 18/187,352 and US 18/189,441, which are currently undergoing review.

What are the key product lines of Xcelerate?

Xcelerate's key product lines include Ceramedx®, a plant-based ceramide therapy system, and various other health and beauty products.

Who are Xcelerate's strategic partners?

Xcelerate partners with Darrow Associates for investor relations and Craft Capital Management for investment banking services.

Where is Xcelerate's headquarters located?

Xcelerate's headquarters are located in Mauldin, South Carolina.

What is the significance of Xcelerate's partnership with the Army & Air Force Exchange Service?

Being an approved vendor allows Xcelerate to sell its products to over 20 million active and retired US Army and Air Force members and their families.

How does Xcelerate plan to grow its business?

Xcelerate aims to enhance global medical care through innovative technologies and expand its product offerings and market reach through strategic partnerships.

What are the company’s financial goals?

Xcelerate is focused on revenue growth through product sales and strategic alliances, with a goal to increase revenues significantly in 2024.

How can investors stay updated on Xcelerate's developments?

Investors can stay updated by visiting Xcelerate's website at https://xcelerate.global/.

XCELERATE INC

OTC:XCRT

XCRT Rankings

XCRT Stock Data

10.73M
254.49M
41.61%
Medical Care Facilities
Healthcare
Link
United States of America
Mauldin